Published in Drug Week, September 10th, 2004
The CHMP opinion recommends authorization of once-every-3-week Aranesp administration in the treatment of anemia in adult cancer patients with non-myeloid malignancies who are receiving chemotherapy and up to once-per-month administration in the treatment of anemia in chronic kidney disease (CKD) patients not on dialysis.
"With the majority of cancer patients receiving chemotherapy on a 21-day cycle, the opportunity to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.